What is the current landscape of antibodies targeting membrane proteins? As of June 2022, 162 antibodies had been approved for a wide array of diseases in the world, including cancers, immune-related diseases, infectious diseases, and hematological diseases1. Over half target membrane proteins, primarily proteins with large extracellular domains and simple transmembrane domains such as tyrosine…

By Sino Biological Therapeutic monoclonal antibodies have emerged as the fastest-growing class of therapeutics since the mid-1980s from the increasing number of pharmaceutical companies seeking more drug modalities to extend their pipelines. Additionally, biosimilars now have more opportunities to enter the market as patents of some blockbuster monoclonal antibodies begin to expire. Given this context,…